24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

Peter Fickert, Martin Wagner, Hanns Ulrich Marschall, Andrea Fuchsbichler, Gernot Zollner, Oleksiy Tsybrovskyy, Kurt Zatloukal, Jie Liu, Michael P. Waalkes, Cathleen Cover, Helmut Denk, Alan F. Hofmann, Hartmut Jaeschke, Michael Trauner

Research output: Contribution to journalArticle

234 Scopus citations

Abstract

Background & Aims: Current therapy for primary sclerosing cholangitis is of limited efficacy. Multidrug resistance gene 2 knockout mice (Mdr2 -/-) represent a well-characterized model for sclerosing cholangitis. Experiments were performed to test in such mice the therapeutic effects of 24-norUrsodeoxycholic acid, a C23 homologue of ursodeoxycholic acid with 1 fewer methylene group in its side chain. Methods: Mdr2-/- mice were fed a diet containing 24-norUrsodeoxycholic acid (0.5% wt/wt) or ursodeoxycholic acid (0.5% wt/wt) as a clinical comparator for 4 weeks; controls received standard chow. Effects on serum liver tests, liver histology, markers of inflammation and fibrosis, and bile acid transport and metabolism were compared. 24-norUrsodeoxycholic acid metabolism was studied in serum, liver, bile, and urine. Results: 24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes. 24-norUrsodeoxycholic acid underwent extensive phase I/II metabolism (hydroxylation, sulfation, and glucuronidation), thereby increasing the hydrophilicity of biliary bile acid secretion. There was a coordinated induction of bile acid detoxifying enzymes (Cyp2b10, Cyp3a11, and Sult2a1) and efflux pumps (Mrp3 and Mrp4). Ursodeoxycholic acid, in contrast, increased alanine transaminase and alkaline phosphatase levels, had no significant effects on hydroxyproline content, and induced biliary transporters and detoxification enzymes to a much smaller extent than 24-norUrsodeoxycholic acid. Conclusions: 24-norUrsodeoxycholic acid ameliorates sclerosing cholangitis in Mdr2 -/- mice. Its therapeutic mechanisms involve (1) increasing the hydrophilicity of biliary bile acids, (2) stimulating bile flow with flushing of injured bile ducts, and (3) inducing detoxification and elimination routes for bile acids.

Original languageEnglish (US)
Pages (from-to)465-481
Number of pages17
JournalGastroenterology
Volume130
Issue number2
DOIs
StatePublished - Feb 2006

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of '24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice'. Together they form a unique fingerprint.

  • Cite this

    Fickert, P., Wagner, M., Marschall, H. U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., Zatloukal, K., Liu, J., Waalkes, M. P., Cover, C., Denk, H., Hofmann, A. F., Jaeschke, H., & Trauner, M. (2006). 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 130(2), 465-481. https://doi.org/10.1053/j.gastro.2005.10.018